Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA BIOMED TO PRESENT AT 2014
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima , the Company ) today advised that the
Western Association of Gynecologic Oncologists (WAGO) Program Committee has accepted the abstract entitled Treatment with Mucin 1-Autologous Dendritic Cell Therapy Significantly Improves Progression-Free Survival in Ovarian Cancer Patients in
Second Remission for oral presentation at the Ovarian Cancer Session at the 2014 WAGO Annual Meeting to be held from June 25-28, 2014 in California.
Dr. Heidi Gray, lead investigator, will deliver a presentation on final progression free survival (PFS) and interim overall survival (OS) data for Epithelial
Ovarian Cancer patients in First or Second Remission (the CAN-003 protocol). As outlined in her presentation to the American Society of Clinical Oncology (ASCO) Annual Meeting on 31 May and as previously announced, Dr Gray will highlight the
positive trends demonstrated in PFS and OS for CVac in the second remission patient population.
The following are specific details
regarding Prima s presentation.
Date: Thursday, June 26, 2014
Time: 10:35am 10:45am
Location: Ritz Carlton Lake Tahoe, Salon III
Prima BioMed is a globally active
leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize
value to shareholders. Prima s lead product is CVac , an autologous dendritic cell- based product currently in clinical trials. www.primabiomed.com.au
For further information please contact:
Adam Holdsworth, ProActive Capital
Mr Matthew Gregorowski, Citadel
+61 (0) 422 534 755; mgregorowski@citadelpr.com.au
Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889
Mr. Axel M hlhaus, edicto GmbH
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au ABN: 90 009 237 889